Key Highlights

  • Third quarter Revenue rose 11% to USD 1.95 million, ahead of the USD 1.32 million estimate.
  • Net loss narrowed to USD 3.6 million, or USD 0.01 per share, against an estimated loss of USD 0.06.
  • A USD 16.6 million derivative Fair Value gain offset an operating loss of USD 17.8 million.
  • Cash, restricted cash and short-term investments totaled USD 84.6 million, a runway projected into 2028.

Ocugen (NASDAQ:OCGN) reported third quarter collaborative arrangement revenue of USD 1.95 million, up from USD 1.75 million a year earlier and above the USD 1.32 million estimate. The net loss was USD 3.6 million, or USD 0.01 per share, compared with USD 20.1 million, or USD 0.07, a year ago and an estimated loss of USD 0.06 per share. For nine months, the net loss was USD 47.7 million, or USD 0.14 per share.

Why the Loss Narrowed

The improvement came from below the operating line. Research and Development expense rose to USD 12.5 million from USD 11.1 million, while general and administrative expense fell to USD 7.2 million from USD 8.2 million, leaving the operating loss at USD 17.8 million versus USD 17.6 million. A USD 16.6 million gain from the change in fair value of a derivative liability, which did not exist a year earlier, brought total other income to USD 14.2 million, compared with other expense of USD 2.4 million.

Interest expense rose to USD 3.1 million from USD 1.3 million, and interest income increased to USD 0.6 million from USD 0.2 million. Weighted shares were 339.2 million versus 304.0 million. Over nine months, operating expenses were USD 57.0 million, up from USD 50.5 million, and a USD 2.4 million loss on Debt extinguishment was recorded in the first half.

Late-Stage Pipeline and Licensing

Chairman and chief executive Shankar Musunuri said all three modifier gene therapy programs are now in phase 3. Enrollment of 140 patients is complete in the OCU400 trial for retinitis pigmentosa, with top-line data targeted for the first quarter of 2027, followed by a planned BLA submission. The OCU410ST program for Stargardt disease targets top-line data in the second quarter of 2027. In September, the first patient was dosed in ArMaDa3, a 237-subject phase 3 trial of OCU410 in geographic atrophy, with a BLA filing targeted for 2028.

On October 13, Ocugen licensed OCU400 for the Middle East and North Africa to Roots Pharmaceutical. Terms include up to USD 4.0 million in upfront and milestone payments, up to USD 255.0 million in sales milestones and a 22% Royalty on net sales, with Ocugen Manufacturing commercial supply. This follows a South Korea license to Kwangdong. OCU400 also received provisional approval in the Bahamas under that country's regenerative therapies law, with patient enrollment targeted as early as year end.

Cash Position and Runway

Cash and equivalents were USD 24.6 million and short-term investments USD 59.6 million at September 30, compared with USD 18.6 million of cash and no investments at year end. Management said the combined USD 84.6 million, including restricted cash, funds operations into 2028 and covers two of the three late-stage programs through their planned BLA filings. Shares outstanding were 339.3 million. No revenue guidance was provided.

Next Reporting Checkpoints

Quarterly revenue of USD 1.95 million compares with operating expenses of USD 19.7 million. The USD 16.6 million derivative gain compares with the USD 17.8 million operating loss. Cash of USD 84.6 million compares with a nine month operating loss of USD 52.0 million, and the USD 255.0 million of potential Roots sales milestones compares with up to USD 4.0 million in near-term payments.